Revelation Biosciences (NASDAQ:REVB) Stock Price Up 1.4% – Here’s What Happened

Shares of Revelation Biosciences, Inc. (NASDAQ:REVB) were up 1.4% during trading on Wednesday . The stock traded as high as $1.04 and last traded at $1.00. Approximately 17,999 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 42,725 shares. The stock had previously closed at $0.9866.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, August 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Revelation Biosciences Stock Up 1.4%

The business has a 50-day simple moving average of $1.06 and a two-hundred day simple moving average of $1.12. The company has a market cap of $3.98 million, a price-to-earnings ratio of -0.08 and a beta of -0.14.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.01. As a group, equities analysts anticipate that Revelation Biosciences, Inc. will post -5.18 earnings per share for the current year.

Institutional Investors Weigh In On Revelation Biosciences

Large investors have recently added to or reduced their stakes in the stock. Sabby Management LLC boosted its position in Revelation Biosciences by 192.5% during the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after purchasing an additional 398,651 shares during the period. Armistice Capital LLC raised its position in shares of Revelation Biosciences by 442.8% in the fourth quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after purchasing an additional 354,272 shares during the period. Finally, Geode Capital Management LLC bought a new position in shares of Revelation Biosciences in the fourth quarter valued at approximately $27,000. Institutional investors own 12.80% of the company’s stock.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.